The French-Canadian validation of a disease-specific, patient-reported outcome measure for lupus

Lupus

Volumn 23, Issue 14, 2014, Pages 1452-1459

  Bourre Tessier J ^a   Clarke, A E ^b   Kosinski, M ^c   Mikolaitis Preuss, R A ^d   Bernatsky, S ^e   Block, J A ^d   Jolly, M ^d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Outcomes Insight Consulting Division   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

quality of life; self assessment; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CANADA; CANADIAN; CONVERGENT VALIDITY; COPING BEHAVIOR; CRITERION RELATED VALIDITY; DEMOGRAPHY; DISCRIMINANT VALIDITY; DISEASE ACTIVITY; FEMALE; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PHYSICIAN; REPRODUCTION; SEROLOGY; SEXUAL HEALTH; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TEST RETEST RELIABILITY; VALIDATION STUDY; VISUAL ANALOG SCALE; BODY IMAGE; COGNITION; COMPLICATION; EMOTION; LANGUAGE; MIDDLE AGED; MOTIVATION; PAIN; PSYCHOLOGY; PSYCHOMETRY; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ADULT; BODY IMAGE; CANADA; COGNITION; EMOTIONS; FEMALE; GOALS; HEALTH STATUS; HUMANS; LANGUAGE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PAIN; PATIENT OUTCOME ASSESSMENT; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84911066599     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314543921     Document Type: Article

References (29)

1. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?. J Rheumatol. 2005 ; 32: 1706-1708
2. Thakkar A, Mikolaitis RA, Block JA, Jolly M. Caregiver burden is associated with worse dyadic relationship and health outcomes in lupus?. Arthritis Rheum. 2011 ; 63 (Suppl). 557
3. Guidance for industry. Systemic Lupus Erythematosus - Developing Medical Products for Treatment, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072063.pdf (accessed June 2011).
4. Jolly M, Pickard AS, Block JA, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012 ; 42: 56-65
5. Toloza SM, Jolly M, Alarcón GS. Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: Cross-cultural issues. Curr Rheumat Rep. 2010 ; 12: 237-249
6. Bourré-Tessier J, Clarke AE, Mikolaitis-Preuss RA, et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Canada. J Rheumatol. 2013 ; 40: 1327-1333
7. Navarra S, Tanangunan R, Mikolaitis-Preuss R, Kosinski M, Block J, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus. 2013 ; 22: 262-267
8. Jolly M, Toloza S, Block J, et al. Spanish LupusPRO: Cross-cultural validation study for lupus. Lupus. 2013 ; 22: 431-436
9. Kaya A, Goker B, Cura ES, et al. Turkish LupusPRO: Cross-cultural validation study for lupus. Clin Rheumatol. Epub ahead of print 11 August. 2013 ;:
10. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol. 1993 ; 46: 1417-1432
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725
12. Ware JE Quality of life and pharmacoeconomics in clinical trials. Spiker B, ed. Philadelphia: Lippincott-Raven ; 1996: 337-345.
13. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
14. Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011 ; 20: 453-462
15. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369
16. Aday LA Designing and conducting health surveys. 2 nd ed. San Francisco, CA: Jossey-Bass Inc, a Wiley Company, 1996. San Francisco, CA: Jossey-Bass Inc, a Wiley Company ; 1996 :
17. Di Fabio RP In:Essentials of rehabilitation research: A statistical guide to clinical practice. Philadelphia: F.A. Davis Company ; 2013: 60-61.
18. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equa Model. 1999 ; 6: 1-55
19. Mplus user's guide computer program. Los Angeles: Muthén & Muthén ; 2001 :
20. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res. 1993 ; 2: 441-449
21. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: Consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000 ; 9: 322-327
22. Statistics Canada: Population by knowledge of official languages, 2006 census. http://www.statcan.gc.ca/tables-tableaux/sum-som/cst01/dem015-cng.htm (accessed June 2011).
23. Devilliers H, Amoura Z, Besancenot JF, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012 ; 51: 1906-1915
24. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology. 2005 ; 44: 1267-1276
25. Doward LS, McKenna SP, Whalley D, et al. The development of the L-QoL: A quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2008 ; 59: 84-88
26. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007 ; 57: 972-979
27. Jolly M, Cornejo J, Mikolaitis RA, Block JA. LupusPRO and responsiveness to changes in health status and disease activity over time (abstract). Arthritis Rheum. 2011 ; 63: S898
28. Devilliers H, Garris C, Kosinski M, Jolly M. Lupus Impact Tracker is responsive to changes in Physician Assessed Disease Status by Systemic Lupus Erythematosus Responder Index (abstract). Arthritis Rheum. 2013 ; 65: S1083
29. Jolly M, Kosinski M, Toloza S, et al. Equivalence of various language versions of lupus specific patient reported outcomes measure (LupusPRO) (abstract). Arthritis Rheum. 2012 ; 64: S607